Acacia Research Corp  

(Public, NASDAQ:ACTG)   Watch this stock  
Find more results for ACTG
+0.33 (6.48%)
Real-time:   1:56PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.02 - 5.48
52 week 2.82 - 10.63
Open 5.25
Vol / Avg. 1.31M/330,527.00
Mkt cap 276.41M
P/E     -
Div/yield     -
EPS -3.16
Shares 50.46M
Beta 1.09
Inst. own 82%
Jul 28, 2016
Q2 2016 Acacia Research Corp Earnings Call
Jul 28, 2016
Q2 2016 Acacia Research Corp Earnings Release
Jun 9, 2016
Acacia Research Corp Annual Shareholders Meeting
May 13, 2016
Acacia Research Corp Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -40.03% -125.95%
Operating margin -39.25% -122.06%
EBITD margin - 35.93%
Return on average assets -11.54% -35.62%
Return on average equity -13.06% -40.50%
Employees 42 -
CDP Score - -


520 Newport Center Drive, 12Th Floor
United States - Map
+1-949-4808300 (Phone)
+1-949-4808301 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Acacia Research Corporation, through its subsidiaries, is engaged in patent investment, prosecution, licensing and enforcement activities. The Company's subsidiaries partner with inventors and patent owners for patented inventions. The Company operates in patent licensing and enforcement business segment. The Company's subsidiaries generate revenues from the granting of intellectual property rights for the use of patented technologies that its subsidiaries control or own. The Company's subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. It is engaged in licensing and enforcing patented technologies. Its subsidiaries include Adaptix, Inc. and Body Science, LLC.

Officers and directors

Paul R. Ryan Chairman and CEO
Robert L. (Chip) Harris II President and Director
Clayton J. Haynes SVP, Finance, CFO, and Treasurer
Marvin E Key Interim Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Clayton J. Haynes Chief Financial Officer, Senior Vice President - Finance, Treasurer
Age: 45
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Edward J. Treska Senior Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
Frank E. Walsh III Director
Age: 48
Bio & Compensation  - Reuters
William S. Anderson Independent Director
Age: 56
Bio & Compensation  - Reuters
Fred A. deBoom Independent Director
Age: 79
Bio & Compensation  - Reuters
Edward W. Frykman Independent Director
Age: 79
Bio & Compensation  - Reuters